Comparative Pharmacology
Head-to-head clinical analysis: BUTORPHANOL TARTRATE PRESERVATIVE FREE versus DALGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTORPHANOL TARTRATE PRESERVATIVE FREE versus DALGAN.
BUTORPHANOL TARTRATE PRESERVATIVE FREE vs DALGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butorphanol is a mixed agonist-antagonist opioid analgesic acting at mu- and kappa-opioid receptors; it exerts its analgesic effects primarily via kappa-opioid receptor agonism and partial mu-opioid receptor agonism/antagonism.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Adults: 1-2 mg intramuscularly or intravenously every 3-4 hours as needed for pain; alternatively, 0.5-1 mg intravenously every 3-4 hours. For epidural administration: 1-2 mg at the lumbar level, may repeat once after 60 minutes if needed.
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours (IV); 4-6 hours (IM). In hepatic impairment, half-life may increase to 5-9 hours; in renal impairment, minimal change unless severe.
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
Primarily renal (70-80% as unchanged drug and metabolites; 5% unchanged), biliary/fecal (15-20%), with enterohepatic recirculation.
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic